CD8A and neoplasm: For instance, Han et al. [11] showed that loss of YTHDF1 in classical dendritic cells enhanced the cross-presentation of tumour antigens and the cross-priming of CD8+ T cells in vivo, and YTHDF1 may be a potential therapeutic target in anticancer immunotherapy.